A temperature-sensitive phase-change hydrogel of tamoxifen achieves the long-acting antitumor activation on breast cancer cells
Open Access
- 1 May 2019
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 3919-3931
Abstract
Background: Breast cancer is one of the foremost threats to female health nowadays. Tamoxifen, an antagonist of estrogen receptor-α (ERα), is the first choice for endocrine-dependent breast cancer (ERα-positive breast cancer) treatment. However, ERα has an important function in the normal physical regulation of estrogen, and current oral administration of tamoxifen has potential side effects on normal endocrine secretion. In the present work, we aim to develop novel approaches to increase the antitumor effect of tamoxifen on breast cancer cells and decrease the potential side effects in the human body during treatment. Methods: A temperature-sensitive phase-change hydrogel for tamoxifen (Tam-Gel) was generated. After establishing subcutaneous tumors formed by MCF-7, an ERα-positive breast cancer cell line, in nude mice, an intratumoral injection of Tam-Gel was performed to examine whether Tam-Gel facilitated the slow-release or antitumor effect of tamoxifen. A metastatic breast cancer model was established using the intrahepatic growth of MCF-7 cells in immunodeficient rats. Results: Tam-Gel can transform from liquid to hydrogel at room temperature. An intratumoral injection of Tam-Gel facilitated the slow-release or antitumor effect of tamoxifen. Once Tam-Gel, but not Tam-Sol, was administered by intratumoral injection, it significantly decreased the uptake of radionuclide probes (18F-fluoroestradiol or 18F-fluorodeoxyglucose) by cells in rats’ livers and the intrahepatic growth of MCF-7 cells in rats’ livers. Conclusion: A novel slow-release system was successfully prepared to facilitate the long-term release of tamoxifen in breast cancer tissues, and achieved an antitumor effect in the long term.Keywords
This publication has 54 references indexed in Scilit:
- Highly sensitive simultaneous quantification of estrogenic tamoxifen metabolites and steroid hormones by LC-MS/MSAnalytical and Bioanalytical Chemistry, 2015
- Simultaneous Determination of Centchroman and Tamoxifen Along with Their Metabolites in Rat Plasma Using LC–MS/MSBioanalysis, 2015
- Quantification of Tamoxifen in Pharmaceutical Formulations Using Micellar Liquid ChromatographyAnalytical Sciences, 2014
- A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related CancersCurrent Medicinal Chemistry, 2014
- Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesisJournal of Clinical Investigation, 2013
- Cross-talk between HER2 and MED1 Regulates Tamoxifen Resistance of Human Breast Cancer CellsCancer Research, 2012
- Combinatorial Nanoparticles for Cancer Diagnosis and TherapyCurrent Medicinal Chemistry, 2012
- Four-and-a-half-LIM protein 1 down-regulates estrogen receptor α activity through repression of AKT phosphorylation in human breast cancer cellThe International Journal of Biochemistry & Cell Biology, 2012
- Intravesical drug delivery: Challenges, current status, opportunities and novel strategiesJournal of Controlled Release, 2010
- The Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptor (SMRT) Corepressor Is Required for Full Estrogen Receptor α Transcriptional ActivityMolecular and Cellular Biology, 2007